Research of Ovarian Yolk Sac Tumor has been linked to Neoplasms, Yolk Sac Tumor, Ovarian Neoplasm, Mesonephric Tumor, Germ Cell Tumor. The study of Ovarian Yolk Sac Tumor has been mentioned in research publications which can be found using our bioinformatics tool below. Researched pathways related to Ovarian Yolk Sac Tumor include Localization, Drug Resistance, Menstruation, Cell Proliferation, Lactation. These pathways complement our catalog of research reagents for the study of Ovarian Yolk Sac Tumor including antibodies and ELISA kits against AFP, TRIM26, CARCINOEMBRYONIC ANTIGEN, ALPHA FETOPROTEIN, MUC16.
Ovarian Yolk Sac Tumor Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Ovarian Yolk Sac Tumor below!
For more information on how to use Laverne, please read the How to Guide.
We have 1416 products for the study of Ovarian Yolk Sac Tumor that can be applied to Flow Cytometry, Chromatin Immunoprecipitation, Western Blot, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Ovarian Yolk Sac Tumor is also known as Endodermal Sinus Tumor Of Ovary, Endodermal Sinus Tumor Of The Ovary, Endodermal Sinus Tumour Of Ovary, Ovarian Endodermal Sinus Tumor, Yolk Sac Tumor Of The Ovary.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.